Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/126250
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPadrones, Susana-
dc.contributor.authorGarcia Vidal, Carolina-
dc.contributor.authorFernández-Serrano, Silvia-
dc.contributor.authorFernández Cervilla, Ana Belén-
dc.contributor.authorMasuet Aumatell, Cristina-
dc.contributor.authorCarratalà, Jordi-
dc.contributor.authorCorominas Sánchez, Mercè-
dc.contributor.authorArdanuy Tisaire, María Carmen-
dc.contributor.authorGudiol i Munté, Francesc-
dc.contributor.authorManresa, Federico-
dc.contributor.authorDorca i Sargatal, Jordi-
dc.date.accessioned2018-11-20T09:20:30Z-
dc.date.available2018-11-20T09:20:30Z-
dc.date.issued2010-10-
dc.identifier.issn0934-9723-
dc.identifier.urihttp://hdl.handle.net/2445/126250-
dc.description.abstractThe aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on β-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with β-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p = 0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.-
dc.format.extent9 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Verlag-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s10096-010-0993-0-
dc.relation.ispartofEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010, vol. 29, num. 10, p. 1243-1251-
dc.relation.urihttps://doi.org/10.1007/s10096-010-0993-0-
dc.rights(c) Springer Verlag, 2010-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationPneumococs-
dc.subject.classificationAntibiòtics-
dc.subject.classificationCitoquines-
dc.subject.otherStreptococcus pneumonia-
dc.subject.otherAntibiotics-
dc.subject.otherCytokines-
dc.titleImpact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec580668-
dc.date.updated2018-11-20T09:20:31Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid20567869-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
580668.pdf379.51 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.